Technology
Business roundup: Grant to advance mitochondrial biomarker research
Age Tech World explores the latest business developments in the world of ageing and longevity.
Grant to advance groundbreaking mitochondrial biomarker research
Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, has announced a US$350,000 grant to Minovia Therapeutics, a clinical-stage company pioneering mitochondrial transplantation technologies.
The funding will support Minovia’s research proposal to develop novel mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and function, with the goal of establishing a standardised “MitoScore.”
In addition to developing mitochondrial augmentation and transplantation (MAT)-based therapies, Minovia has set dual goals: advancing biomarkers to measure mitochondrial health and using these biomarkers to compare mitochondrial scores in healthy individuals and patients with mitochondrial disease.
By doing so, Minovia aims to provide tools for earlier diagnosis, better disease tracking, and more effective evaluation of therapies.
Mitochondrial dysfunction is a hallmark not only of rare genetic diseases but also of chronic and age-related conditions.
Despite its central role in human health, impacting the brain, heart, muscles, metabolism, and immunity, there are no approved therapies or functional diagnostic tests for mitochondrial dysfunction.
When mitochondria become damaged or stop working properly, cells fail to produce enough energy, triggering a ripple effect that undermines nearly every system in the body. Causes can range from genetics and aging to environmental toxins, infections, poor diet, chronic stress, and medications.
Because dysfunction often hides behind seemingly unrelated symptoms, it is frequently misdiagnosed or missed entirely, earning its reputation as the “hidden root cause” of disease.
“We shouldn’t just be fixing disease; we should be funding the future of health and healing,” said Mitzi Solomon, Founder & President of Countdown For A Cure Foundation.
“Supporting Minovia’s biomarker work is a crucial step in advancing mitochondrial medicine to the forefront of healthcare, not only for patients living with rare mitochondrial diseases, but also for the millions worldwide facing conditions linked to mitochondrial dysfunction.
“As one of the most overlooked drivers of health and disease, mitochondrial dysfunction plays a central role in everything from neurodegeneration and chronic fatigue to aging and metabolic disorders.
“By addressing this profound unmet need, we have an opportunity to transform how medicine prevents, diagnoses, and treats disease at its root.”
First hydrogen-based therapy with the potential to target Alzheimer’s disease unveiled
H2 Medical Technologies, part of the H2 Global Group, has developed the world’s first functional hydrogen-based therapy medical device prototype for clinical trials — aimed at both preventing and treating Alzheimer’s disease.
H2 Global Group will present this breakthrough at LSI Europe 2025 in London, one of the world’s most prestigious MedTech and HealthTech conferences.
The project builds on more than 30 years of research and patents developed with Professor Shigeo Ohta, a global leader in molecular hydrogen science and co-founder of H2 Global Group.
While the immediate focus is Alzheimer’s, potential applications extend to neurological disorders, brain regeneration, and healthy ageing.
Until now, the project has been funded primarily by Czech investors. H2 Global Group is now opening the door to US and global partners at a critical growth stage, with EU registration underway and FDA approval next on the horizon, unlocking the world’s largest healthcare market.
The global Alzheimer’s therapeutics market is projected to exceed $20 billion by 2030, with dementia-related costs already surpassing $1 trillion annually. Positioned as the only functional hydrogen-based therapy of its kind, H2 Global Group offers investors a rare first-mover advantage in one of the most urgent and lucrative markets of our time.
“This is not another experiment – it is the first technology in the world with the potential to prevent Alzheimer’s disease before it even starts, while supporting those already affected,” said David Marsalek, founder and CEO of H2 Global Group.
“Our mission is clear: to turn decades of research into real hope for millions of families around the world. We are part of a strong vision of a society where hydrogen is the molecule of life that connects the world.”
Clock.bio appoints former BioNTech executive as chief business officer
Rejuvenation biology company, clock.bio, which is developing therapies to reverse ageing and extend healthspan, has announced the appointment of Dr. Michael Boehler, former BioNTech executive, as chief business officer.
Dr. Boehler will lead the company’s business development, strategic partnerships, and commercialisation efforts, working closely with the leadership team to advance clock.bio‘s breakthrough rejuvenation biology platform.
“Michael played a central role in one of the most significant product launches in pharmaceutical history,” said Markus Gstöttner, CEO of clock.bio.
“His experience in BioNTech’s global commercial scale-up, combined with his proven ability to build partnerships, makes him uniquely suited to help clock.bio translate breakthrough science into therapies that extend healthspan.”
Dr. Boehler joins clock.bio with more than 20 years of global experience in the life sciences industry, spanning commercial, general management, and business development roles.
At BioNTech, he was instrumental in transforming the company from a clinical-stage biotech into a global pharmaceutical leader. He built the company’s global commercial organization, established BioNTech’s first integrated country organisation in Europe, and contributed to its successful IPO.
His commercial strategy and execution were critical to the vaccine’s worldwide distribution, which reached billions of people across multiple continents.
Prior to BioNTech, Dr. Boehler held senior leadership positions at Takeda, Kite Pharma, and Amgen, building deep therapeutic expertise, particularly in oncology. Most recently, he has worked as an advisor, angel investor, and board member to early-stage biotech companies.
“Rejuvenation biology is one of the most exciting frontiers in medicine,” said Dr. Michael Boehler, chief business officer of clock.bio.
“What drew me to clock.bio is its unique ability to decode the rejuvenation genome and turn those insights into meaningful interventions. I’m excited to help shape the path that brings this science from discovery toward therapies that can transform human healthspan.”
Zimmer Biomet announces new chief medical advisors to help improve standard of musculoskeletal care
Global medical technology company Zimmer Biomet Holdings has announced the appointments of Jonathan Vigdorchik, as chief medical technology advisor focused on adult reconstruction and hip implants, and Anand Murthi, as chief medical advisor, shoulder, sports, extremities, and trauma (S.E.T.).
As strategic advisors, Vigdorchik and Murthi will leverage their extensive clinical experience to help guide the company’s new product pipeline and portfolio strategy across their respective areas of focus, and enhance Zimmer Biomet’s medical education initiatives.
Dr. Vigdorchik is a board-certified, fellowship-trained orthopaedic surgeon at Hospital for Special Surgery (HSS) in New York City, specialising in hip and knee replacement surgery.
Dr. Murthi is a board-certified, fellowship-trained orthopaedic surgeon who serves as Chief of Shoulder and Elbow Surgery and Director of the Shoulder and Elbow Fellowship Program at MedStar Union Memorial Hospital in Baltimore.
“These appointments reflect Zimmer Biomet’s commitment to deepening clinical collaboration and accelerating advancements across our portfolio – from implants and robotic technology to sports medicine and extremities,” said Ivan Tornos, chairman, president and CEO at Zimmer Biomet.
“We’re proud to welcome them both as strategic partners in helping to redefine the future of musculoskeletal care.”
In these roles, Drs. Vigdorchik and Murthi will assist with our medical education and surgeon engagement; advise on the Company’s technology and implant strategy and development roadmap; and serve as strategic liaisons between Zimmer Biomet and the broader surgical community.
A new brain health collaboratory from Cognito and Ochsner aims to test new ways of treating cognitive decline and Alzheimer’s disease.
The Brain Health Collaboratory is described as the Gulf South’s first statewide platform for non-invasive brain health innovation.
It will combine Cognito’s investigational Spectris technology with Ochsner’s clinical network to explore care models across urban and rural communities in the region.
Dr David Houghton, system chair of neurology at Ochsner Health, said: “This new collaboratory affords us the opportunity to pair emerging neurotechnology with real-world clinical care to better understand how we can slow cognitive decline, improve patients’ lives and open new therapeutic pathways for other neurological diseases in the future.”
At the centre of the initiative is Spectris, an investigational device for use at home that delivers synchronised light and sound stimulation through the brain’s natural sensory pathways.
The technology is designed to support healthy neural network activity and, according to its developers, has shown early promise in helping preserve brain structure and function in Alzheimer’s disease.
It received Breakthrough Device Designation from the US Food and Drug Administration in 2021 and is currently being evaluated in clinical trials.
The two organisations will also work on a Brain Health Index, a framework intended to track cognitive health, disease progression and treatment response in real-world care settings.
The programme will explore how Spectris could be integrated into clinical care models for patients experiencing cognitive decline.
Cambridge, Massachusetts-based Cognito Therapeutics describes itself as a late clinical-stage neurotechnology company focused on non-invasive neuroprotective therapies for neurodegenerative diseases.
Ochsner Health is the leading nonprofit healthcare provider in Louisiana, Mississippi and across the Gulf South, operating 47 hospitals and more than 370 health and urgent care centres.
The collaboratory will also explore ways to integrate the technology into programmes serving patients eligible for both Medicare and Medicaid, the US government health insurance schemes, where Alzheimer’s disease places a significant clinical and economic burden.
Christian Howell, chief executive officer of Cognito Therapeutics, said: “Ochsner’s reach across the Gulf South provides a unique opportunity to bring innovative brain health technologies to a broad patient population.
“Partnerships like this are essential to ensuring that new therapies can reach patients not just in major academic centres, but across entire healthcare systems that serve both urban and rural communities.
“Expanding access to patients is critical to generating real-world evidence and ultimately delivering new options for people living with Alzheimer’s disease.”
The Ochsner partnership is the second such collaboratory for Cognito, which launched its first in November 2025 with the West Virginia University Rockefeller Neuroscience Institute.
The company says it plans to build a broader network of collaboratories with health systems and academic medical centres to expand patient access and generate real-world evidence.
The Spectris technology may also have potential in a range of other neurological conditions, including Parkinson’s disease, multiple sclerosis, traumatic brain injury, stroke and addiction, according to the company.
However, it remains investigational and has not yet received regulatory approval.
A centenarian study by HLI and LEV Foundation will examine why some people live past 100 and remain healthier for longer.
The collaboration will study blood samples from centenarians and supercentenarians, people aged 100 and 110 or over, to explore the biology of exceptional longevity.
Researchers are trying to answer a central question in ageing science: why do individuals age at different rates?
The study will use multi-omic analysis, including genomics and proteomics, which examine genes and proteins, to identify biomarkers and biological pathways linked to exceptional longevity.
Wei-Wu He, executive chairman at HLI, said: “Centenarians and supercentenarians offer natural insights in human ageing.
“By applying our precision longevity platform to those who have achieved exceptional longevity, we can better understand how to preserve health in late life for everyone.
“The knowledge gained here has the potential to reshape how we approach aging and age-related disease.”
The organisations say these rare groups represent a unique biological resource.
Their blood samples may contain molecular and cellular information that helps explain why some people age more slowly and maintain good health for longer than the wider population.
Building on those analyses, the study is expected to provide new insights into the mechanisms behind exceptional longevity and differences in ageing.
Comparative analyses of exceptionally long-lived people and broader population cohorts will aim to identify key molecular features of extreme longevity and help lay the groundwork for future longitudinal studies.
Human Longevity, Inc. (HLI) and LEV Foundation announced the collaboration. HLI, founded in 2013 and based in South San Francisco, says it integrates genomics, artificial intelligence and multimodal diagnostics to extend human healthspan.
LEV Foundation, founded in 2022, is a California-based nonprofit focused on extending healthy human lifespan, with its flagship Robust Mouse Rejuvenation study series examining combinations of promising anti-ageing interventions.
The project is being spearheaded by Natalie S. Coles-de Grey, who the organisations say brings decades of expertise in the study of supercentenarians.
Both Coles-de Grey and LEVF’s president and chief science officer, Aubrey de Grey, are joining HLI’s scientific advisory board.
de Grey said: “I’m delighted that LEVF is partnering with HLI to further both organizations’ goals.
“There is so much to be learned, from the oldest old in our society, that will refine the preventative medicine for the chronic conditions of late life that HLI has pioneered.
“Such work is immensely complementary to LEVF’s focus on mice, and I’m sure that this collaboration will have synergy that will save many future lives.”
The organisations said findings from the study are expected to contribute to the growing field of longevity science and may inform the development of diagnostics, therapeutics and preventive strategies aimed at extending healthspan across the global population.
By Ruth Dixon, Programme Lead, Challenge Works
Humans are social creatures – connection to others is vital for good health and wellbeing.
Despite this, research conducted last year showed that almost one out of every four older individuals in the world feels lonely – a significant and saddening statistic.
Research has consistently shown that people who become socially isolated as they get older are more likely to develop dementia.
Furthermore, people who already have dementia tend to experience a faster decline of their symptoms when they are socially isolated.
This was particularly evident during COVID lockdowns when people with dementia were cut off from their social networks.
Faced with an aging population, we must ensure that people can continue to grow old with dignity, remain independent and stay connected with loved ones after a dementia diagnosis – something that artificial intelligence is helping to make possible.
Technology to combat social isolation
While there is no silver bullet to combat social isolation, there are technologies available that can help to support people to remain independent in their own home and maintain connections with their friends, family and community.
Doing so can help to preserve their dignity, identity and sense of purpose while reducing stress and anxiety through familiar surroundings.
It allows them to maintain daily routines and cognitive function for longer by living in a comfortable environment with known, consistent layouts.
Thanks to the rapidly evolving technological landscape, we are venturing far beyond basic solutions.
AI and machine learning enables innovators to support those living with dementia directly (not just their caregivers) and in turn, better mitigate the risk of social isolation – with more than three quarters (77 per cent) of family doctors believing this type of technology will help people with dementia to live longer.
Designing with and for people living with dementia
However, for dementia technology to be effective, it needs to be designed with, not just for, the end user.
MemoryAid is a fantastic example of a co-created solution.
Designed to be reminiscent of a traditional telephone, MemoryAid is a home assistant device that has been developed specifically for and with people living with dementia to help them make video calls and stay connected.
The touchscreens on everyday smartphones and tablets are not always designed with older users in mind.
Smartphones and tablets need to be kept charged and require dexterous movements, be it swiping, tapping or clicking small buttons to make or answer a call – a challenge for many people, let alone someone living with a neurodegenerative condition.
Rather than having to navigate a touchscreen device – to make and answer video calls with loved ones, friends and caregivers – MemoryAid users simply pick up the handset, a familiar action from a lifetime of practice, deeply ingrained in cognitive and muscle memory.
It was one of five international finalists in the Longitude Prize on Dementia – a global prize rewarding the development of assistive technologies for and with people living with dementia.
The £1 million grand prize was awarded to CrossSense, a revolutionary AI companion built into smart glasses to help people maintain their independence, in a ceremony last week.
But of course, it’s not just virtual connection that makes a difference to independence at home, physical safety matters too, especially in maintaining face-to-face relationships.
Enabling physical safety
A very different innovation, that also ran for the Longitude Prize on Dementia, is Theora360 – a wearable device to support people to live confidently at home without the fear of falling or wandering, enabling greater autonomy over their day to day lives.
Venturing outside independently can be difficult for people with cognitive impairments like dementia, with the fear of getting lost or falling and sustaining a serious injury presenting a barrier to leaving the house with confidence.
While most falls only result in minor injury, sometimes they can have a more serious impact – leading to a loss of mobility, independence and self-esteem.
Events such as hospitalisation and relocation can induce a range of negative experiences. A fall may cause someone to become home or bed-bound.
For someone with dementia, this may cause further distress as they may be unable to remember the cause of their injury or how to manage it effectively.
They are also more likely to experience worsening mental function as a result of pain or delirium.
If someone falls or wanders, Theora360 can alert a carer or loved one in real time, enabling rapid intervention. The sooner help can reach someone, it’s likely that the health consequences for them will be less severe.
The technology empowers people to retain agency over their social life, to go for their weekly coffee with a neighbour or visit the post office reassured that the support and assistance is there if they need it.
Facilitating meaningful moments
But where will AI take care next?
Solutions are continuously evolving.
The Theora 360 team, for example, is currently working with Texas A&M University to develop predictive capabilities based on changes in gait, to identify when a fall is likely and prevent it from happening in the first place.
There’s no doubt that technology is helping to shift the dial when it comes to combatting social isolation for people living with dementia.
By empowering people to remain independent, boosting confidence and helping to eliminate fear, AI can be a way to facilitate some of the most real and most meaningful moments between people.
Ruth Dixon is a Programme Lead at Challenge Works, a global leader in the design and delivery of open innovation challenge prizes for social good.
The Longitude Prize on Dementia is funded by Alzheimer’s Society and Innovate UK.
Gut-friendly foods may damage heart, charity warns
Diabetes patients face increased risk of undiagnosed heart failure
UK government announces £6.3m fund to boost men’s health
Brain health collaboratory launches in Gulf South
